The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) has issued updated recommended acceptable intake limits for a group of chemical contaminants known as nitrosamine drug substance-related impurities, or NDSRIs. The information, posted in the agency’s “CDER Nitrosamine Impurity Acceptable Intake Limits” resource on FDA.gov, is intended to guide drug manufacturers on how much of these impurities can be present in medicines while still being considered acceptable from a safety standpoint.
According to the FDA’s published materials, the updated limits refine earlier recommendations and are part of an ongoing effort to manage nitrosamine risks in human drugs.
What the FDA Updated
The FDA’s CDER page on nitrosamine impurities lists recommended acceptable intake limits for various nitrosamines that can appear in drug products. Nitrosamines are a class of compounds that, at certain levels and over long-term exposure, are associated with an increased cancer risk. The FDA’s document focuses specifically on nitrosamine drug substance-related impurities—NDSRIs—which are nitrosamines that can form from the active ingredient or other components within a drug.
In its updated information, CDER provides:
- Recommended acceptable intake limits for specific NDSRIs, expressed as daily exposure levels that are considered to pose a very low cancer risk over a lifetime
- Clarifications on how these limits should be applied by drug manufacturers when assessing the safety of their products
- Updated listings of which NDSRIs have established limits and which are still under evaluation
The FDA presents these values as recommendations intended to support risk assessment and control strategies in drug manufacturing. The agency’s materials indicate that these limits are based on toxicological evaluations and are designed to align with a very low theoretical excess cancer risk over a lifetime of exposure.
Why Nitrosamine Limits Matter
Nitrosamines can form during the manufacture or storage of some medicines. The FDA’s CDER resource explains that NDSRIs may arise when certain chemical structures in active ingredients or excipients (inactive components) react under specific conditions, such as during synthesis, formulation, or storage.
Because some nitrosamines are classified as probable or possible human carcinogens based on animal studies, regulators set conservative intake limits to keep any potential added cancer risk very low. The CDER page notes that acceptable intake limits are typically calculated to correspond to a one-in-100,000 additional lifetime cancer risk, assuming daily exposure at the limit for 70 years.
By updating its recommended limits, the FDA is giving manufacturers a clearer benchmark for evaluating whether the amount of a given NDSRI in a product is acceptable or whether further process changes, testing, or mitigation measures are needed.
How Drug Manufacturers Are Expected to Use the Limits
The CDER nitrosamine resource explains that acceptable intake limits are intended to be used as part of a structured risk assessment and control strategy. Manufacturers are expected to:
- Identify potential NDSRIs that could form in their products based on the chemistry of the active ingredient and manufacturing process
- Test products when a risk is identified, using methods capable of detecting nitrosamines at or below the recommended limits
- Compare measured levels of NDSRIs in finished products to the FDA’s acceptable intake limits
- Take action—such as modifying the manufacturing process, improving storage conditions, or reformulating—if levels exceed the recommended limits
The updated information on FDA.gov emphasizes that these limits are recommendations rather than legally binding standards. However, they reflect the agency’s current scientific assessment of what levels are considered acceptable from a safety perspective. CDER’s guidance signals how the agency is likely to evaluate nitrosamine findings during inspections, application reviews, or safety assessments.
What This Means for Patients and Providers
The FDA’s CDER materials frame the updated acceptable intake limits as part of a broader effort to keep medicines as safe as possible while maintaining access to needed treatments. The agency notes that the presence of a nitrosamine at or below the recommended acceptable intake limit does not mean a medicine is unsafe; instead, it indicates that any added cancer risk from that impurity is considered very low.
For patients and healthcare providers, the immediate effect of the updated limits is largely indirect. The recommendations are aimed at drug manufacturers and regulatory reviewers rather than at prescribers or the public. However, they can influence how companies:
- Decide whether to continue manufacturing a product while they work to reduce nitrosamine levels
- Adjust processes to prevent NDSRI formation
- Communicate with the FDA if unexpected nitrosamine levels are detected
The CDER resource underscores that patients should not stop taking their medications without consulting a healthcare professional, even if nitrosamine concerns are reported, because the risk of untreated disease can outweigh the theoretical cancer risk from low-level impurities.
What to Watch Next
The FDA indicates through its CDER nitrosamine page that work on NDSRIs is ongoing. The list of nitrosamines with established acceptable intake limits is expected to evolve as new data become available and as additional impurities are identified and evaluated.
Readers following this issue can watch for:
- Further updates to the CDER nitrosamine acceptable intake table on FDA.gov
- Additional NDSRIs being added to the list with specific limits
- Any new FDA communications to manufacturers about timelines or expectations for controlling nitrosamine levels in marketed products
The updated acceptable intake limits for nitrosamine drug substance-related impurities mark another step in the FDA’s effort to systematically identify, evaluate, and control these contaminants. For now, the key development is that manufacturers have refreshed, FDA-recommended benchmarks to guide how they monitor and manage NDSRIs in human drugs.
